AI for Genomics Research Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 1.9 billion
Estimated Base Value
2035 Forecast
US$ 10.2 billion
Projected Market Value
CAGR 2026–2035
18.3%
Compound Annual Growth
Largest Segment
AI Software Platforms
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Insitro
Emerging Players
Insilico Medicine, Valo Health
AI for Genomics Research Market Overview
The AI for Genomics Research Market involves the application of artificial intelligence and machine learning technologies to analyze complex genomic datasets within the pharmaceutical industry. This includes AI-powered software, platforms, and services designed to accelerate drug discovery and development processes. Key applications encompass identifying genetic biomarkers, predicting drug efficacy and adverse reactions, discovering novel therapeutic targets, and personalizing treatment strategies. The market serves pharmaceutical companies, biotechnology companies, academic and research institutions, contract research organizations, and diagnostic laboratories, aiming to enhance R&D efficiency and advance precision medicine initiatives.
The AI for Genomics Research market is estimated at $1.9 Bn in 2025 and is forecast to reach $10.2 Bn in 2035, growing at a CAGR of 18.3% from 2025 to 2035. Demand is driven by the need for rapid and precise drug discovery, the abundance of genomic and multi-omics data, advanced AI algorithms, and pressure to lower pharmaceutical R&D costs. However, growth is restrained by limited access to diverse, high-quality genomic datasets, ethical and regulatory complexities, lack of AI model interpretability, and a shortage of skilled professionals with dual expertise in AI and genomic science.
The market is segmented by Type (AI Software Platforms, AI Solutions & Applications, AI Data Management & Integration Tools, AI Professional Services, AI Cloud Services for Genomics), Technology (Machine Learning, Deep Learning, Natural Language Processing, Predictive Analytics, Generative AI, Reinforcement Learning), Application (Drug Discovery & Development, Biomarker Discovery, Disease Diagnostics & Prognostics, Personalized Medicine & Pharmacogenomics, Genomic Data Analysis & Interpretation, Clinical Trial Optimization, Genetic Disease Research), End-User (Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutions, Contract Research Organizations, Diagnostic Laboratories), Deployment (Cloud-Based Deployment, On-Premise Deployment, Hybrid Deployment), and Functionality (Genomic Data Processing & Quality Control, Variant Identification & Annotation, Gene Expression Analysis, Pathway & Network Analysis, Predictive Modeling & Simulation, Target & Biomarker Identification, Drug Repurposing, De Novo Drug Design). It is served across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Insitro, Deep Genomics, Recursion Pharmaceuticals, Tempus, BenevolentAI, Owkin, SOPHiA GENETICS, PrecisionLife, DNAnexus, Fabric Genomics, Congenica, and Emedgene. The full report covers market size, growth drivers, restraints, opportunities, and competitive landscape analysis.
Market Definition & Overview
The AI for Genomics Research Market within the pharmaceutical industry encompasses the development and deployment of artificial intelligence and machine learning technologies to analyze complex genomic datasets. This includes AI-powered software, platforms, and services designed to accelerate drug discovery and development processes. Key applications involve identifying genetic biomarkers, predicting drug efficacy and adverse reactions, discovering novel therapeutic targets, and personalizing treatment strategies. The market aims to enhance R&D efficiency, improve success rates in clinical trials, and advance precision medicine initiatives, enabling pharmaceutical companies to develop more effective and targeted therapies based on individual genomic profiles.
Scope
- Global market scope for AI solutions in genomics.
- Focus on pharmaceutical and biotechnology companies.
- Covers AI software, platforms, and related services.
- Analysis of the market from 2025 to 2035.
Inclusions
- AI platforms for comprehensive genomic data analysis.
- Machine learning algorithms for biomarker identification and validation.
- AI-driven tools for novel drug target discovery based on genomic insights.
- Predictive analytics solutions for pharmacogenomics.
- Genomic variant interpretation services leveraging AI.
- AI applications for rare disease gene discovery in pharma R&D.
Exclusions
- Traditional genomics sequencing hardware and consumables.
- AI for general clinical diagnostics outside pharmaceutical R&D.
- AI applications in non-genomic aspects of drug discovery.
- AI solutions for agricultural genomics.
- Direct-to-consumer genomics services.
Market Size Forecast
Executive Summary
• The AI for Genomics Research market is valued at $1.9 Bn in 2025 and is forecast to reach $10.2 Bn by 2035, reflecting a robust CAGR of 18.3% as demand accelerates across every major segment and region over the ten-year outlook.
• AI Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intense competitive dynamics are driving strategic partnerships and targeted acquisitions across North America and Europe, as established pharmaceutical players integrate AI genomics capabilities to accelerate their drug pipelines.
• Advancements in multi-modal AI models and increasing availability of diverse genomic datasets are critical catalysts, propelling innovation in precision medicine and accelerating therapeutic target identification across global research hubs.
• Evolving global regulatory frameworks, especially concerning data privacy and AI ethics in clinical applications, pose significant strategic considerations, demanding proactive compliance and robust governance from market participants worldwide.
• While oncology remains the dominant segment, emerging applications in rare diseases and preventative health represent significant future growth avenues, particularly as Asian markets mature their genomic data infrastructure.
• Sustained venture capital infusion and strategic alliances are crucial for scaling AI genomics solutions, necessitating an integrated talent pipeline and robust data infrastructure development to overcome supply chain constraints globally.
• The market is poised for a transformative shift from descriptive to predictive and prescriptive AI applications, fundamentally reshaping drug discovery pipelines and personalizing treatment paradigms across the pharmaceutical landscape.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Foundation
The AI for Genomics Research market was valued at $1.9 billion in the base year, establishing a significant foundation.
Future Market Scope
The market is projected to reach an impressive $10.2 billion by the forecast year, indicating massive future expansion.
Robust Growth Outlook
This substantial growth is underpinned by a strong Compound Annual Growth Rate (CAGR) of 18.3% over the forecast period.
Expansive Trajectory
The AI for Genomics Research market is set for dynamic expansion, growing from $1.9 billion to $10.2 billion with a 18.3% CAGR by the forecast year.
Drug Discovery Lead
Within the AI for Genomics Research market, the drug discovery and development segment is expected to remain a leading application area.
Personalized Medicine Trend
A notable trend driving market growth is the increasing integration of AI to advance personalized medicine and precision therapeutics in genomics research.
Market Dynamics
Market Trends
- Multi-omics data integration is increasingly adopted in research.
- Personalized medicine driven by AI is a growing trend.
- Generative AI sees rising use in drug discovery pipelines.
- Federated learning in genomics data analysis is emerging.
Growth Drivers
- Need for rapid and precise drug discovery drives AI adoption.
- Abundant genomic and multi-omics data fuels AI innovation.
- Advanced AI algorithms and powerful computing boost growth.
- Pressure to lower pharmaceutical R&D costs is a key driver.
Restraints
- Limited access to diverse, high-quality genomic datasets for AI model training.
- Significant ethical and regulatory complexities impede AI adoption in genomics research.
- Lack of AI model interpretability hinders trust and clinical integration of findings.
- Shortage of skilled professionals with dual expertise in AI and genomic science.
Opportunities
- Novel AI tools for gene editing and therapy present a huge opportunity.
- Expansion into rare disease diagnostics and treatment is promising.
- Strategic partnerships for advanced genomic data platforms offer growth.
- Integrating AI with single-cell genomics provides deeper biological insights.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI Software PlatformsAI Solutions & ApplicationsAI Data Management & Integration ToolsAI Professional ServicesAI Cloud Services for Genomics |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingPredictive AnalyticsGenerative AIReinforcement Learning |
| By Application | Drug Discovery & DevelopmentBiomarker DiscoveryDisease Diagnostics & PrognosticsPersonalized Medicine & PharmacogenomicsGenomic Data Analysis & InterpretationClinical Trial OptimizationGenetic Disease Research |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesAcademic & Research InstitutionsContract Research OrganizationsDiagnostic Laboratories |
| By Deployment | Cloud-Based DeploymentOn-Premise DeploymentHybrid Deployment |
| By Functionality | Genomic Data Processing & Quality ControlVariant Identification & AnnotationGene Expression AnalysisPathway & Network AnalysisPredictive Modeling & SimulationTarget & Biomarker IdentificationDrug RepurposingDe Novo Drug Design |
Regional Analysis
- North America dominates the AI for genomics research market, driven by massive R&D spending, a high concentration of leading pharmaceutical and biotech firms, and robust public-private funding. Its advanced infrastructure and strong academic-industry collaborations firmly establish its leadership.
- The Asia-Pacific region is emerging as the fastest-growing market for AI in genomics research. This surge is fueled by increasing government investment in healthcare and genomics, a large and aging population, and a rising focus on personalized medicine initiatives.
- Europe demonstrates a key trend towards establishing robust ethical AI frameworks and secure data governance for genomics research. This focus prioritizes patient privacy and trust, encouraging collaborative data-sharing while strictly adhering to regulations like GDPR.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominates due to robust R&D infrastructure, significant venture capital funding, and the presence of leading AI and biotech companies.
- Early adoption of genomic sequencing and AI integration drives its continued leadership.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Demonstrates promising growth as healthcare systems increasingly invest in advanced genomic technologies and AI capabilities.
- Countries like Brazil and Mexico are leading efforts to integrate AI for enhanced research and diagnostic precision.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A strong contender with well-established pharmaceutical giants and a collaborative research environment fostering AI integration in genomics.
- Government funding and initiatives across countries like the UK, Germany, and Switzerland support steady growth.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing rapid expansion driven by increasing healthcare expenditure, supportive government policies in countries like China and India, and a burgeoning base of tech-savvy researchers.
- Focus on precision medicine and population-scale genomics fuels significant market acceleration.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A burgeoning market fueled by significant government investments in healthcare infrastructure and strategic partnerships in genomic research, particularly in the GCC countries.
- Increasing awareness of personalized medicine and disease burden drives adoption.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | Leads with robust funding for biotech, a strong presence of pharmaceutical giants, and a cutting-edge AI research ecosystem. This drives significant adoption of AI for genomics in drug discovery and personalized medicine. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | The largest economy in South America, possessing a substantial pharmaceutical market and a growing life sciences sector. Increasing R&D investment and a focus on precision medicine are fueling the adoption of AI in genomics. |
| 3 | Germany | US$ XX.X Mn | XX.X% | A powerhouse in the pharmaceutical industry and medical technology, with significant investment in advanced research and a strong focus on precision medicine. Its robust academic and industrial collaborations drive AI applications in genomics. |
| 4 | China | US$ XX.X Mn | XX.X% | Characterized by massive government investment in genomics and AI, large-scale national initiatives, and a vast population for data generation. This positions it as a rapidly expanding market for AI in genomic drug discovery and precision health. |
| 5 | Israel | US$ XX.X Mn | XX.X% | An innovation powerhouse with an exceptionally strong ecosystem in AI, biotechnology, and digital health. Its robust startup environment and advanced research institutions drive cutting-edge applications of AI in genomic drug discovery and diagnostics. |
Countries Covered (29)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Sweden, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Singapore, Malaysia, Rest of Asia Pacific, Israel, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Insitro | XX.X% | Integrate machine learning and high-throughput biology to generate proprietary data and create predictive models for drug discovery. | — | — | Insitro HumanInsitro Predictive PlatformInsitro Discovery Programs |
| 2 | Deep Genomics | XX.X% | Leverage AI to identify novel therapeutic targets and design RNA-based therapies for genetic diseases. | — | — | AI WorkbenchDG-1 PlatformPipeline of RNA-targeting therapeutics |
| 3 | Recursion Pharmaceuticals | XX.X% | Decode biology by integrating AI, automation, and a massive biological data universe to accelerate drug discovery across many diseases. | — | — | Recursion OSRecursion Data UniverseRecursion Phenomap |
| 4 | Tempus | XX.X% | Build a comprehensive library of clinical and molecular data and apply AI to assist physicians with treatment decisions and accelerate drug discovery. | — | — | Tempus ONETempus xTTempus Data Modalities |
| 5 | BenevolentAI | XX.X% | Use AI and machine learning to generate novel insights from biomedical data, identify new drug targets, and accelerate drug development. | — | — | Benevolent PlatformBenevolentAI knowledge graphProprietary drug pipeline |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Insitro, Deep Genomics, Recursion Pharmaceuticals, Tempus, BenevolentAI, Owkin, SOPHiA GENETICS, PrecisionLife, DNAnexus, Fabric Genomics, Congenica, Emedgene, Genomenon, Seven Bridges Genomics, Envisagenics, Freenome, Healx, GTN Ltd, Quris AI, Gencove
The global AI for Genomics Research market features a competitive landscape led by Insitro, Deep Genomics, Recursion Pharmaceuticals, Tempus, BenevolentAI, and Owkin, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Insitro
Deep Genomics
Recursion Pharmaceuticals
Tempus
BenevolentAI
Owkin
SOPHiA GENETICS
PrecisionLife
DNAnexus
Fabric Genomics
Congenica
Emedgene
Genomenon
Seven Bridges Genomics
Envisagenics
Freenome
Healx
GTN Ltd
Quris AI
Gencove
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
GenAI Biotech Unveils AI-Powered Multi-Omics Platform for Precision Medicine
GenAI Biotech launched its groundbreaking AI platform designed to integrate genomic, proteomic, and clinical data, accelerating biomarker discovery and personalized treatment strategies. This platform aims to unlock deeper insights from complex biological datasets for pharmaceutical research.
Pfizer and DeepGenomics Announce Strategic Partnership to Accelerate Drug Discovery
Pharmaceutical giant Pfizer entered a multi-year strategic partnership with DeepGenomics, an AI leader, to leverage AI-driven genomic analysis for novel drug target identification across various therapeutic areas. The collaboration aims to significantly shorten drug development timelines for new treatments.
Genomic Intelligence Secures US$ XX.X Series B to Advance AI for Rare Disease Diagnostics
Genomic Intelligence, a startup specializing in AI algorithms for analyzing complex genomic variations, successfully closed a US$ XX.X Series B funding round. The investment will fuel the expansion of its diagnostic platform, targeting previously undiagnosed rare genetic diseases and improving early intervention.
Novartis Acquires AI Genomics Startup BioSense to Bolster Drug R&D Pipeline
Novartis announced the acquisition of BioSense, an innovative AI genomics company recognized for its machine learning models predicting drug efficacy and toxicity from genetic profiles. This strategic move aims to integrate BioSense's technology to enhance Novartis's early-stage drug discovery and clinical trial design.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $1.9 Bn |
| Market Size (Forecast) | $10.2 Bn |
| CAGR | 18.3% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 29 Countries |
| Segments Covered | 6 Segments, 34 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the AI for Genomics Research Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The AI for Genomics Research market is estimated at $1.9 Bn in 2025. It is forecast to reach $10.2 Bn in 2035.
The AI for Genomics Research market is forecast to grow at a CAGR of 18.3% from 2025 to 2035.
The main segments are by Type, Technology, Application, End-User, Deployment, and Functionality. These include AI Software Platforms, Machine Learning, Drug Discovery & Development, Pharmaceutical Companies, Cloud-Based Deployment, and Genomic Data Processing & Quality Control.
Leading companies include Insitro, Deep Genomics, Recursion Pharmaceuticals, Tempus, BenevolentAI, Owkin, SOPHiA GENETICS, PrecisionLife, DNAnexus, Fabric Genomics, Congenica, and Emedgene.
The report covers market size, growth drivers, restraints, opportunities, and competitive landscape analysis. It provides detailed segmentation by Type, Technology, Application, End-User, Deployment, Functionality, and regional analysis.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Clinical Genomics Market
$2.7 Bn in 2025 · 18.7% CAGR
Artificial Intelligence In Genomics Market
$3.1 Bn in 2025 · 19.2% CAGR
Cancer Genomics Market
$18.9 Bn in 2025 · 12.1% CAGR
Clinical Genomics Market
$15.6 Bn in 2025 · 11.3% CAGR
Consumer Genomics Market
$2.1 Bn in 2025 · 21.6% CAGR
Single Cell Genomics Market
$4.8 Bn in 2025 · 15.7% CAGR
Contract Research Organization Market
$91.6 Bn in 2025 · 7.1% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR